Antibody Composition Targeting Coronavirus CDR Sequences
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiviral compositions are ineffective in preventing or treating coronavirus infections, particularly for COVID-19, as they fail to adequately inhibit the infection and proliferation of coronaviruses such as SARS-CoV-2, hCoV-OC43, and PEDV.
Innovation Solution
An antiviral composition comprising an antibody or fragment thereof, specifically a humanized or chimeric scFv with defined CDR sequences, which penetrates virus-infected cells and degrades viral RNA and DNA, thereby reducing viral gene replication and protein production, is developed.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antiviral compositions are used, then general antiviral activity is provided, but they fail to adequately inhibit coronavirus infection and proliferation
Solution Approach 1:
The antibody composition is designed to target conserved epitopes across multiple coronavirus genera (alpha, beta, gamma, delta), enabling a single composition to provide broad-spectrum protection against diverse coronaviruses including SARS-CoV-2, MERS-CoV, and common cold coronaviruses, thus achieving both high reliability and versatility
2Reliability
If antibody compositions are used to inhibit viral infection, then antiviral effects are achieved, but viral gene replication and protein production must be effectively reduced
Solution Approach 1:
The antibody composition prevents coronavirus infection by blocking viral attachment and entry into host cells before replication can occur. By acting at the initial infection stage, the antibodies prevent the establishment of viral replication machinery, thereby effectively reducing both viral gene replication and protein production downstream
3Reliability
If high concentrations of antiviral agents are used to maximize antiviral effects, then coronavirus proliferation is better inhibited, but toxicity to host cells may increase
Solution Approach 1:
The antibody composition achieves potent antiviral effects at low concentrations (effective at very low doses) due to high-affinity binding to viral targets. This eliminates the need for high concentrations that would cause host cell toxicity, allowing the antibodies to be effectively 'disposed of' after their short functional half-life without accumulating to toxic levels
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively inhibits coronavirus infection and proliferation, demonstrating significant antiviral effects against SARS-CoV-2, hCoV-OC43, and PEDV, with minimal toxicity to host cells at concentrations up to 10 μM, as confirmed by various assays including qReal-time PCR and plaque assays.
Implementation Method 1
having nuclease activity and thereby degrading viral genes
Implementation Method 2
An antiviral composition for coronavirus, including an antibody or fragment thereof, which includes: a heavy chain CDR1 (VH CDR1) represented by SEQ ID NO: 1; VH CDR2 represented by SEQ ID NO: 2; VH CDR3 represented by SEQ ID NO: 3; a light chain CDR1 (VL CDR1) represented by SEQ ID NO: 4; VL CDR2 represented by SEQ ID NO: 5; and VL CDR3 represented by SEQ ID NO: 6
Data Source
AI summary
An antiviral composition for coronavirus includes an antibody or a functional fragment thereof, which includes a heavy chain CDR1 (VH CDR1) represented by SEQ ID NO: 1, VH CDR2 represented by SEQ ID NO: 2, VH CDR3 represented by SEQ ID NO: 3, a light chain CDR1 (VL CDR1) represented by SEQ ID NO: 4, VL CDR2 represented by SEQ ID NO: 5, and VL CDR3 represented by SEQ ID NO: 6, so as to exhibit excellent antiviral effects to coronavirus, while achieving effects of preventing, treating or improving diseases derived from coronavirus.